Last updated: December 31, 2024
Sponsor: Mostafa Bahaa
Overall Status: Active - Recruiting
Phase
2/3
Condition
Gastrointestinal Diseases And Disorders
Treatment
Mesalamine
Dapagliflozin 10mg Tab
Clinical Study ID
NCT05986136
Tanta 1234
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥ 18 years
Both male and female will be
Mild and moderate UC patients diagnosed and confirmed by endoscope
Exclusion
Exclusion Criteria:
Breast feeding
Significant liver and kidney function abnormalities
Colorectal cancer patients
Patients with severe UC
Patients taking rectal or systemic steroids
Patients taking immunosuppressives or biological therapies
Addiction to alcohol and / or drugs
Known allergy to the dapagliflozin
Study Design
Total Participants: 50
Treatment Group(s): 2
Primary Treatment: Mesalamine
Phase: 2/3
Study Start date:
August 20, 2023
Estimated Completion Date:
July 20, 2028
Connect with a study center
Faculty of Medicine, Mansoura University
Mansoura, 7650001
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.